Skip to main navigation Skip to search Skip to main content

Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

  • David Fiorentino
  • , Aaron R. Mangold
  • , Victoria P. Werth
  • , Lisa Christopher-Stine
  • , Alisa Femia
  • , Myron Chu
  • , Amy C.M. Musiek
  • , Jason C. Sluzevich
  • , Lauren V. Graham
  • , Anthony P. Fernandez
  • , Rohit Aggarwal
  • , Kerri Rieger
  • , Karen M. Page
  • , Xingpeng Li
  • , Craig Hyde
  • , Natalie Rath
  • , Abigail Sloan
  • , Barry Oemar
  • , Anindita Banerjee
  • , Mikhail Salganik
    • Christopher Banfield, Srividya Neelakantan, Jean S. Beebe, Michael S. Vincent, Elena Peeva, Ruth Ann Vleugels

Research output: Contribution to journal › Article › peer-review

31   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry